Scholl Hendrik Peter sold 500 shares of BELITE BIO, INC on Nov 12, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Medical Officer
Chief Medical Officer
Filed Nov 16, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
500American depositary share
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
3.45%This security and ownership context
Holdings after
14,000Indirect · By Bioptima Ltd.
Trade date
Nov 12, 2026Sell
Filed
Nov 16, 2026, 7:13 PM ET5-day reporting delay
Accession
0001193125-26-464091Code S · Transaction 402213
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 14,500 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Sell500——Trade 402214
Nov 12, 2026Sell500——Trade 402215
Nov 12, 2026Sell500——Trade 402216
4 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

BLTE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BLTE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −6.6%1w ago −12%1d ago −4.1%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026.